“Specific Detection of HER-2 positive tumors in mice using superparamagnetic relaxometry” is the title of a poster presented by Erika Vreeland, PhD, at the 2017 World Medical Imaging Congress. The poster data, showing high sensitivity and the selective ability of tumor-targeting MagSense nanoparticles to discriminate between HER2-overexpressing and non-overexpressing cancer cells in mice, contribute to the evidence Imagion Biosystems is building in support of the company’s plan for first-in-human clinical trials.
Download the poster “Specific detection of HER-2 positive tumors in mice using superparamagnetic relaxometry (SPMR).”
Prestige Biopharma and Imagion Biosystems Sign an MOU, Developing Early Pancreatic Cancer Diagnosis Platform
SINGAPORE, and San Diego, California – Prestige Biopharma, a biopharmaceutical company specializing in innovative antibody therapies, with a strong dedication to tackling pancreatic cancer, and Imagion